Skip to content

Celldex Therapeutics

US · CLDX #2630 by market cap Listed 1970
27.42 -0.54 -1.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Morgan Stanley Initiates Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $61
    Market Newswire · 2026/11/10
  • Company notice
    Celldex Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
    SEC · 2026/11/6
  • Morgan Stanley Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $61
    Market Newswire · 2026/11/9
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Summit Therapeutics (SMMT) and AbbVie (ABBV)
    TipRanks · 2026/10/14
  • Rating change
    HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target
    Benzinga · 2026/10/2
  • Rating change
    LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $64
    Market Newswire · 2026/9/28
  • A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $29 to $68
    Market Newswire · 2026/11/7
  • Celldex Therapeutics Price Target Raised to $68.00/Share From $60.00 by Canaccord Genuity
    Dow Jones · 2026/11/10
  • Rating change
    H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64
    Market Newswire · 2026/10/5
  • Company notice
    Celldex Therapeutics | 8-K: Current report
    SEC · 2026/9/22
  • Rating change
    LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64
    Market Newswire · 2026/10/3
  • Company notice
    Celldex Therapeutics | SCHEDULE 13G/A: Others
    SEC · 2026/10/7
  • Rating change
    Barclays Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $53
    Market Newswire · 2026/11/6
  • CCORF Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $68
    Market Newswire · 2026/11/9
  • Company notice
    Celldex Therapeutics | 8-K: Celldex Reports Third Quarter Financial Results and Provides Corporate Update
    SEC · 2026/11/6
  • Rating change
    Cantor Fitzgerald Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $72
    Market Newswire · 2026/10/14
  • Rating change
    Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $72
    Market Newswire · 2026/10/15
  • Rating change
    A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $50 to $88
    Market Newswire · 2026/9/24
  • Company notice
    Celldex Therapeutics | 10-Q: Quarterly report
    SEC · 2026/11/6
  • Rating change
    Morgan Stanley Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $57
    Market Newswire · 2026/10/20
  • Rating change
    Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
    Benzinga · 2026/9/23
  • Rating change
    Celldex Therapeutics Is Maintained at Overweight by Morgan Stanley
    Dow Jones · 2026/9/23
  • Company notice
    Celldex Therapeutics | SCHEDULE 13G/A: Others
    SEC · 2026/8/15
  • Rating change
    A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $50 to $100
    Market Newswire · 2026/9/23
  • Rating change
    Celldex Therapeutics Is Maintained at Outperform by Leerink Partners
    Dow Jones · 2026/9/23

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Celldex Therapeutics discussion 0 comments

Add a comment